BioLineRx (BLRX) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 18, 2021 7:00 AM EST- Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combination with G-CSF -
- Pre-NDA meeting with FDA set for mid-December; NDA submission planned for H1 2022 -
- Cash and cash equivalents at September 30, 2021 of $62.2 million -
- Management to hold conference call today, November 18, at 10:00 am EST -
TEL AVIV, Israel, Nov. 18, 2021 /PRNewswire/ --Â BioLineRx Ltd. (NASDAQ: BLRX) (TASE:... More
